reports
BioXcel Therapeutics Announces Positive Results from Correlation Study...
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes Completes clinical trials required by FDA for sNDA submission planned for the first quarter of 2026 NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive results from the correlation study related to exploratory efficacy outcomes from the SERENITY At-Home trial. The results, along w...
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Cele...
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel’s breakthrough pr...
e-therapeutics relance son activité sous le nom de Tangram Therapeutic...
e-therapeutics relance son activité sous le nom de Tangram Therapeutics et présente LLibra OS Ce renouveau marque une étape décisive dans la croissance de la Société, qui prévoit de soumettre sa première demande d’essai clinique (ou CTA, de l’anglais « Clinical Trial Application ») au quatrième trimestre 2025. Présentation de LLibra OS, une plateforme d’IA de nouvelle génération visant à accélérer la découverte et l’évaluation de cibles génétiques différenciées et la conception de petits ARN interférents (siRNA, de l’anglais « small interfering RNA »). LONDRES, 02 oct. 2025 (GLOBE NEWSW...
e-therapeutics startet als Tangram Therapeutics neu und stellt LLibra ...
e-therapeutics startet als Tangram Therapeutics neu und stellt LLibra OS vor Der Relaunch markiert den entscheidenden nächsten Schritt für das Wachstum des Unternehmens – in Erwartung der ersten CTA-Einreichung im vierten Quartal 2025. Vorstellung von LLibra OS, einer KI-Plattform der nächsten Generation, die die Entdeckung und Bewertung differenzierter Gen-Targets und das siRNA-Design beschleunigt. LONDON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tangram Therapeutics (ehemals e-therapeutics), ein Unternehmen, das sich der Vereinigung von Computertechnologie und RNAi zur schnelleren Herstellun...
e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra O...
e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025. Introducing LLibra OS, a next-generation AI platform that accelerates discovery and evaluation of differentiated gene targets and siRNA design. LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tangram Therapeutics (formerly e-therapeutics), a company committed to uniting computation and RNAi to make better medicines faster, today announced its corporate relaunch. Tangram Therapeutics is inspired by a geometric...
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Li...
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the market value of listed securities (“MVLS”) requirement under Nasdaq Listing Rule 5550(b)(2) (the “...
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Dat...
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Glo...
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference to be held September 8 - 10, 2025. Date: Monday, September 8, 2025Time: 4:30 p.m. Eastern TimeWebcast Link: The live an...
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phas...
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial ...
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety...
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Fol...
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home...
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 Company to host conference call at 8 a.m. ET, August 27, 2025 NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will host an investor call and live webcast at 8 a.m. ET, August 27, 2025 to review topline da...
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivot...
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of the database lock for its SERENITY At-Home pivotal Phase 3 safety tr...
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments ...
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received positive pre-sNDA meeting respo...
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@...
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a virtual fireside chat on Thursday, August 14, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series. Date: Tuesday, August 14, 2025Time: 1 p.m. Eastern TimeWebcast Link: About BioXcel T...
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and...
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Publication of non-clinical data in Frontiers in Pharmacology suggests potential applications of BXCL501 in chronic conditions BioXcel Therapeutics strengthens cash position NEW HAVEN, Conn., Aug. 12, 2025 ...
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual G...
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference NEW HAVEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, Aug. 12, 2025, at 12 p.m. ET. To access a webcast of the fireside chat, please visit the under the “News/Events...
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacolog...
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation Leading academic institutions are evaluating BXCL-501 in clinical studies for multiple chronic conditions NEW HAVEN, Conn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasd...
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-...
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today ...
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Mee...
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia Pre-Supplemental New Drug Application meeting with FDA scheduled for August 20, 2025 NEW HAVEN, Conn., July 21, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscienc...
e-therapeutics reduziert Risiken im klinischen Verfahren für GalOmic-K...
e-therapeutics reduziert Risiken im klinischen Verfahren für GalOmic-Kandidaten ETX-312 dank positiver Ergebnisse in der vorklinischen Phase ETX-312 wurde in GLP-konformen Toxikologiestudien in überhöhten Dosierungen gut vertragen GMP-konforme Herstellung einer Charge für klinische Studien erfolgreich abgeschlossen Auf Kurs für die Einreichung bei der CTA im vierten Quartal 2025 LONDON, July 11, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, ein Unternehmen, das Rechenleistung und biologische Daten integriert, um lebensverändernde RNAi-Medikamente zu entdecken, gab heute bedeutende...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.